Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boulder/denver blog main
boulder/denver top stories
clinical trials
9
×
detroit blog main
9
×
detroit top stories
indiana blog main
indiana top stories
life sciences
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
9
×
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boston top stories
fda
national
cancer
europe blog main
europe top stories
glaxosmithkline
novartis
abbvie
amgen
cancer immunotherapy
immunotherapy
medical devices
startups
What
roundup
bio
days
drug
fda
biotech
cancer
market
news
patients
therapeutics
time
won
abbvie’s
according
acquisitions
advantages
agency
ahead
aimmune
akcea
allergy
alliance
announced
approval
approved
august
awarded
bar
biofourmis
black
brings
bristol
bucks
busy
buy
calls
cases
celebrate
centers
Language
unset
9
×
Current search:
unset
×
" san francisco blog main "
×
" detroit blog main "
×
" clinical trials "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More